{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T03:47:50Z","timestamp":1782532070322,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.farma.2026.05.002","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T03:42:02Z","timestamp":1782531722000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["[Translated article] Real-world evidence of immune-related adverse events as predictive factor of response in non-small cell lung cancer"],"prefix":"10.1016","author":[{"given":"Maria Susana","family":"Fortes-Gonzalez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Vazquez-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Herrero-Poch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Santome-Couto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Cristina","family":"Cercos-Lleti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2026.05.002_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.farma.2026.05.002_bb0010","author":"National Comprehensive Cancer Network"},{"issue":"10066","key":"10.1016\/j.farma.2026.05.002_bb0015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomized controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.farma.2026.05.002_bb0020","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagn\u00f3stico, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.farma.2026.05.002_bb0025","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1200\/JCO.19.03022","article-title":"Therapy for stage IV non\u2013small-cell lung cancer without driver alterations: ASCO and OH (CCO) Joint Guideline Update","volume":"38","author":"Hanna","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.farma.2026.05.002_bb0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.farma.2026.05.002_bb0035","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.farma.2026.05.002_bb0040","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.farma.2026.05.002_bb0045","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non\u2013small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.farma.2026.05.002_bb0050","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO.19.02446","article-title":"Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1\u2013positive, advanced non\u2013small-cell lung cancer in the KEYNOTE-010 study","volume":"38","author":"Herbst","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.farma.2026.05.002_bb0055","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jtho.2018.04.039","article-title":"Updated efficacy analysis including secondary population results for OAK: a randomized phase iii study of atezolizumab versus docetaxel in patients with previously treated advanced non\u2013small cell lung cancer","volume":"13","author":"Fehrenbacher","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.farma.2026.05.002_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1753465817750075","article-title":"Role of immune-checkpoint inhibitors in lung cancer","volume":"12","author":"Jain","year":"2018","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.farma.2026.05.002_bb0065","doi-asserted-by":"crossref","unstructured":"Jayathilaka B, Mian F, Franchini F, et al. Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review. Br J Cancer 2025 132, 51\u201357. doi:10.1038\/s41416-024-02887-1","DOI":"10.1038\/s41416-024-02887-1"},{"key":"10.1016\/j.farma.2026.05.002_bb0070","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejca.2018.11.002","article-title":"Predictive biomarkers of response for immune checkpoint inhibitors in nonesmall-cell lung cancer","volume":"106","author":"Prelaj","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.farma.2026.05.002_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.farma.2026.05.002_bb0080","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00432-018-2805-3","article-title":"Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis","volume":"145","author":"Ricciuti","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"10.1016\/j.farma.2026.05.002_bb0085","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cllc.2018.10.002","article-title":"Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non\u2013small-cell lung cancer","volume":"20","author":"Grangeon","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.farma.2026.05.002_bb0090","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.farma.2026.05.002_bb0095","first-page":"335","article-title":"Toxicidad inmuno-relacionada asociada al uso de pembrolizumab en la pr\u00e1ctica asistencial","volume":"32","author":"Talens Bol\u00f3s","year":"2022","journal-title":"Rev OFIL ILAPHAR"},{"issue":"2","key":"10.1016\/j.farma.2026.05.002_bb0100","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/10781552211067429","article-title":"Analysis of immune-mediated reactions in patients with non-small cell lung cancer treated with nivolumab and its association with effectiveness","volume":"29","author":"Cortijo-Cascajares","year":"2023","journal-title":"J Oncol Pharm Practice"},{"issue":"5","key":"10.1016\/j.farma.2026.05.002_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15761\/CRR.1000164","article-title":"Real life second-line nivolumab in advanced non-small cell lung cancer: a French observational multicenter study of 259 patients (ABCT-IMMUNOBZH)","volume":"2","author":"Geier","year":"2018","journal-title":"Cancer Rep Rev"},{"key":"10.1016\/j.farma.2026.05.002_bb0110","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.lungcan.2017.11.012","article-title":"Real life experience with nivolumab for the treatment of non-small cell lung carcinoma. Data from the expanded access program and routine clinical care in a tertiary cancer centre\u2014The Netherlands Cancer Institute","volume":"126","author":"Schouten","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.farma.2026.05.002_bb0115","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s11096-018-0772-z","article-title":"A multicentre observational study of the effectiveness, safety and economic impact of nivolumab on non-small-cell lung cancer in real clinical practice","volume":"41","author":"Merino Almaz\u00e1n","year":"2019","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.farma.2026.05.002_bb0120","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.lungcan.2019.05.005","article-title":"Pembrolizumab for advanced nonsmall cell lung cancer: efficacy and safety in everyday clinical practice","volume":"133","author":"Ksienski","year":"2019","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.farma.2026.05.002_bb0125","first-page":"22","article-title":"Efectividad y seguridad en la pr\u00e1ctica cl\u00ednica de anticuerpos anti PD-1\/PD-L1 en monoterapia en el c\u00e1ncer de pulm\u00f3n no microc\u00edtico","volume":"45","author":"Zayas-Soriano","year":"2021","journal-title":"Farm Hosp"},{"issue":"3","key":"10.1016\/j.farma.2026.05.002_bb0130","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1177\/1078155219855127","article-title":"Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy","volume":"26","author":"Weis","year":"2020","journal-title":"J Oncol Pharm Pract"},{"issue":"11","key":"10.1016\/j.farma.2026.05.002_bb0135","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1634\/theoncologist.2017-0384","article-title":"Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell lung cancer treated with nivolumab","volume":"23","author":"Toi","year":"2018","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.farma.2026.05.002_bb0140","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.farma.2026.05.002_bb0145","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2017.08.022","article-title":"Early immune-related adverse events and association with outcome in advanced non\u2013small cell lung cancer patients treated with nivolumab: a prospective cohort study","volume":"12","author":"Teraoka","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.farma.2026.05.002_bb0150","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jtho.2018.11.016","article-title":"Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy","volume":"14","author":"Suresh","year":"2019","journal-title":"J Thorac Oncol"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326001133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326001133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T03:42:08Z","timestamp":1782531728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634326001133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"alternative-id":["S1130634326001133"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2026.05.002","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Real-world evidence of immune-related adverse events as predictive factor of response in non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2026.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2026.03.009","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}